Aug 19- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday. The government's Biomedical Advanced Research and Development Authority will provide up to $20.4 million to fund early development and costs associated with a clinical trial.» Read More
We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.
There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.
Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.
Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.
The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.
Keryx Biopharma is down more than 70 percent after one of its colon cancer drugs failed a late stage clinical trial, with Mark Tepper, Strategic Wealth Partners managing partner.
Discussing the early trial results of the next-generation cholesterol lowering drugs, with Tony Butler, Barclay's managing director/pharmaceuticals analyst.
CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.
Jay Flatley, Illumina CEO, discusses fending off Roche's unsolicited bid as well as the future of his company.
The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.
CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in.
Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.
Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.